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DObjective: For patients with aortic root pathology and aortic valve regurgitation, aortic valve replacement is
problematic because no durable bioprosthesis exists, and mechanical valves require lifetime anticoagulation.
This study sought to assess outcomes of combined aortic valve and root repair, including comparison with
matched bioprosthesis aortic valve replacement.
Methods: From November 1990 to January 2005, 366 patients underwent modified David reimplantation
(n ¼ 72), root remodeling (n ¼ 72), or valve repair with sinotubular junction tailoring (n ¼ 222). Active
follow-up was 99% complete, with a mean of 5.6  4.0 years (maximum 17 years); follow-up for vital status
averaged 8.5 3.6 years (maximum 19 years). Propensity-adjusted models were developed for fair comparison
of outcomes.
Results: Thirty-day and 5-, 10-, and 15-year survivals were 98%, 86%, 74%, and 58%, respectively, similar to
that of the US matched population and better than that after bioprosthesis aortic valve replacement. Propensity-
score–adjusted survival was similar across procedures (P>.3). Freedom from reoperation at 30 days and 5 and
10 years was 99%, 92%, and 89%, respectively, and was similar across procedures (P>.3) after propensity-
score adjustment. Patients with tricuspid aortic valves were more likely to be free of reoperation than those
with bicuspid valves at 10 years (93% vs 77%, P ¼ .002), equivalent to bioprosthesis aortic valve replacement
and superior after 12 years. Bioprostheses increasingly deteriorated after 7 years, and hazard functions for re-
operation crossed at 7 years.
Conclusions: Valve preservation (rather than replacement) and matching root procedures have excellent early
and long-term results, with increasing survival benefit at 7 years and fewer reoperations by 12 years. We recom-
mend this procedure for experienced surgical teams. (J Thorac Cardiovasc Surg 2011;142:1491-8)Supplemental material is available online.e Departments of Thoracic and Cardiovascular Surgery,a Quantitative Health
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The Journal of Thoracic and CarFor patients with aortic root disease and aortic valve regur-
gitation, management of the aortic valve is problematic be-
cause patients present in a similar manner from diverse
disease pathologies that require tailored operative proce-
dures. Although valve replacement is common in such pa-
tients, there is no ideal prosthesis in this circumstance. No
durable bioprosthetic valve replacement device is avail-
able.1-3 Porcine and pericardial valves carry risks of
endocarditis, stroke, and early structural valve failure,
particularly in younger patients, and allografts have no
better durability than bovine pericardial valves when
patient age is taken into account.1 Although the Ross proce-
dure is a reasonable alternative in patients aged less than ap-
proximately 30 years, durability of both the aortic autograft
and the pulmonary allograft is limited.1 Aortic valve re-
placement (AVR) with a mechanical valve carries the risks
of anticoagulation-related hemorrhage, thrombosis, embo-
lization, stroke, endocarditis, and greater blood turbulence,
as seen with high-intensity transient signals.1,2,4-7 Zellner
and colleagues7 report event-free survival of 40% at 10
years for mechanical valves. In addition, in patients under-
going AVR and root and ascending AVR with compositediovascular Surgery c Volume 142, Number 6 1491
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Dmechanical valve grafts, 10-year survival is only 60% and
10-year event-free survival 40%.1,2
Because of these problems, there has been increased
emphasis in young patients on trying to repair the aortic
valve and root to avoid valve replacement. Three ap-
proaches have been described for preserving the aortic
valve while repairing the aortic root: (1) root remodeling
operations (David or Yacoub procedure)3,8-14; (2) aortic
valve reimplantation using various iterations of the
David procedure3,4,8,10,12,15-20; and (3) aortic sinotubular
junction reduction and tailoring procedures, frequently
combined with aortic cusp repair.1,11,12,21-24 We refer to
all 3 as valve-preserving operations.
The objective of this study was to compare outcomes,
particularly long-term survival and risk of reoperation, after
these 3 types of valve-preserving procedures for aortic root
disease accompanied by aortic valve regurgitation.
PATIENTS AND METHODS
Patients
From November 1990 to January 2005, 366 consecutive patients under-
went aortic valve-preserving operations for aortic root disease, excluding
aortic valve stenosis—46 at Lahey Clinic (LGS) and 320 at Cleveland
Clinic. Of these, 72 underwent a modified David reimplantation procedure,
72 underwent aortic root remodeling, and 222 underwent aortic valve re-
pair with sinotubular junction tailoring. Data were collected prospectively
on all patients, supplemented bymedical record review as required, and en-
tered into a database. Data were then collated for analysis (Table E1). Use
of these data for research was approved by the institutional review boards
(IRBs) of both institutions, with patient consent waived.
Surgical Techniques
The surgical techniques, including selection of appropriate approach for
the underlying pathology, have been described extensively by us and
others.1-5,8-25 Aortic arch replacement was performed only for important
dilatation or aortic dissection. Briefly, for degenerative aneurysms, our
surgical preference was a modified David reimplantation operation for
patients with a teardrop-shaped deformity (Erdheim deformity).16,17 For
most patients with bicuspid aortic valves, we used cusp repairs combined
with aortic root remodeling or sinotubular junction tailoring.11,22 If valve
regurgitation appeared to be predominantly related to splaying of the
commissures at the sinotubular junction caused by dilatation, the
preferred procedure was sinotubular junction tailoring and reduction,
with or without aortic cusp or root repair.21 Aortic cusp repair procedures
included narrowing the intercommissural angle by Cabrol sutures, repair-
ing perforations, plicating or resecting excess cusp tissue, placing figure-
of-8 supracommissural cusp sutures, and debriding excess tissue.
Patients who had only aortic valve and commissure resuspension during
repair of aortic dissections were excluded from this study. For the first 30
days after surgery, patients who underwent root-preserving procedures
were placed on a 75-mg daily dose of clopidogrel and thereafter encouraged
to take an aspirin daily. Prophylactic antibiotics for any invasive procedure,
blood pressure control, and use of beta-blockers were also strongly advised.1492 The Journal of Thoracic and Cardiovascular SurEnd Points
Primary end points were (1) all-cause mortality, including in-hospital
deaths, and (2) aortic valve reoperation. For survival reference, age-,
sex-, and race-matched estimates of survival in the US population were cal-
culated. Similarly, a curvewas derived for survival after AVRwith a bovine
pericardial device (Perimount; Carpentier-Edwards, Irvine, Calif) based on
age, sex, New York Heart Association functional class, and concomitant
coronary artery bypass grafting using premarket approval data.26 For reop-
eration reference, age-matched freedom from reoperation for structural
valve degeneration was calculated also from premarket approval data for
bovine pericardial aortic valve prostheses.26
Follow-up
Patients were mailed a letter to obtain permission for an interview and
then contacted by a mailed IRB-approved questionnaire or directly by tele-
phone using an IRB-approved script at 2, 5, 10, and 15 years after surgery.
Mean follow-up was 5.6  4.0 years (maximum 17 years); 2010 patient-
years of data were available for analysis. Follow-up was 99% complete
(all but 1 patient). Among survivors, 10% were followed actively more
than 11 years. For survival, active anniversary follow-up was supplemented
by passive mortality data from the Social Security Death Master File, post-
dated to March 13, 2010. Thus, for survival, mean follow-up was 8.5 3.6
years (maximum 19 years), and 2790 patient-years of data were available
for analysis.
Data Analysis
Study design for fair comparison of outcomes. Because
aortic root techniques were not assigned randomly to each patient, direct
comparison of end points is confounded by selection factors. Therefore,
we approached the analysis from the perspective of study design rather
than outcome analysis.27 From this perspective, we attempted to approxi-
mate a randomized trial and characterize treatment effects for the groups
(rather than seeking risk factors for outcomes) by identifying treatment al-
location factors. For example, patients undergoing reimplantation or re-
modeling were younger than those undergoing tailoring, and patients
undergoing reimplantation were less likely to undergo emergency opera-
tion than were patients undergoing tailoring (Table E1). Patients undergo-
ing reimplantation also were taller and had a larger body surface area than
patients undergoing tailoring, in keeping with our preference for this oper-
ation in patients with Marfan syndrome. Formal identification of treatment
allocation was accomplished by a form of logistic regression analysis that
simultaneously identified factors associated with each of the 3 procedure
groups (polytomous logistic regression). Initially, a model that included
only factors found to be statistically significantly associated with at least
one of the procedures was developed using variables in Table E2 (parsimo-
nious model, Table E3) to describe the nature of treatment decisions. This
was amplified into a propensity model (Table E4) by adding factors from
each class of variables regardless of statistical significance.28,29 From
this model, propensity scores for each type of procedure were calculated
for each patient. These were incorporated into multivariable analyses of
end points, which, in essence, adjusts the estimates of treatment effect
for selection bias.30
Unadjusted time-related estimates. Estimates of unadjusted
overall and stratified survival and freedom from reoperation were obtained
nonparametrically using the Kaplan–Meier method. Estimates were also
obtained by a completely parametric method that automatically decom-
poses time-varying risk (eg, early elevated risk of death after an operation)
into simple components called phases, each of which can be independently
modulated by risk factors, much like mixing primary colors to create a re-
sulting color.31 (For additional details, see http://www.clevelandclinic.org/
heartcenter/hazard.)
Risk-adjusted time-related estimates. Multivariable analyses
for death and reoperation were performed using the multiphase parametricgery c December 2011
Svensson et al Acquired Cardiovascular Diseasehazard model described in the preceding text. Variable selection used bag-
ging32 and the list of candidate risk factors in Table E2. This involved au-
tomated stepwise analysis of 1000 resampled (bootstrap) data sets. This
was followed by tabulating the frequency of occurrence at P  .05 of
both single factors and closely related clusters of factors (eg, transforma-
tions of scale of a single variable to select the one most linear with respect
to outcome, or closely related variables, such as different expressions of pa-
tient size). Variables present in 50% or more of the models were retained
(median rule). Finally, the procedure variables and propensity scores for
more comprehensive risk-adjustment were forced into the models to eval-
uate whether procedure type was associated with these time-related
outcomes.
Presentation. Continuous variables are summarized by mean  stan-
dard deviation unless distributions were skewed, in which case median and
(for consistency) 15th and 85th percentiles are given. Regression coeffi-
cients are accompanied by 1 standard error. For consistency, time-
related estimates are accompanied by 68% confidence limits equivalent
to 1 standard error. Categoric variables are summarized by frequency
and percentage.A
C
DRESULTS
Survival
Unadjusted survivals, including in-hospital deaths, were
98%, 93%, 86%, 74%, and 58%, at 30 days and 1, 5,
10, and 15 years, respectively (Figure E1). The hazard func-
tion had 2 phases: an early rapidly declining phase in the
immediate postoperative period followed by a late slowly
rising phase (Figure E2). For informal reference, after the
early high-risk phase, survival was similar to that of the
age-, sex-, and race-matched US population; survival for
the first 5 years was also similar to that after AVRwith a bio-
prosthesis, and somewhat better thereafter. There were no
30-day or in-hospital deaths after modified David reimplan-
tation of the aortic valve (Table 1).
Patients who were older, had longer aortic clamp time, or
received an elephant trunk graft were at higher risk of early
death (Table E5). Early survival declined more rapidly
when aortic clamp time exceeded 90 minutes (Figure E3).
Unadjusted stratified survival was highest after remodeling
and reimplantation procedures (both 87% at 10 years) andTABLE 1. In-hospital outcomes
Variable
Reimplantation
(total n ¼ 72)
n* No. (%) n*
Hospital death 63 0 (0) 56
Postoperative MI 70 2 (2.9) 71
Blood product usez
RBCs 63 19 (30) 56
Platelets 63 10 (16) 56
FFP 63 6 (9.5) 56
Stroke after operation 72 0 (0) 72
Permanent 72 0 (0) 72
Operative length of stay (d) 62 6 (5–10)x 56
FFP, Fresh-frozen plasma;MI, myocardial infarction; RBC, red blood cell. *Patients with da
or blood products, and in parentheses the percentage who received blood or blood products
received an RBC transfusion. xMedian and 15th and 85th percentiles.
The Journal of Thoracic and Carlowest after sinotubular junction tailoring (66% at 10 years;
Figure 1). However, differences in patient profile among
these groups accounted for the disparity (P  .3; Table E5).
For reference, Figure 1 also shows age-, sex-, and race-
matched survival for the general US population and survival
of matched patients after biologic AVR. Note the better sur-
vival with reimplantation and remodeling compared with
both US survival and matched bioprosthesis survival.
Late survival was lower in older patients and in those un-
dergoing operation earlier in the series (Table E5). Underly-
ing pathology also influenced survival: Marfan syndrome,
100% survival at 10 years; bicuspid valve, 93% survival
at 10 years; aortic dissection, 60% survival at 10 years;
and degenerative aneurysm, 71% survival at 10 years
(Figure 2). Four patients were known to have died late
from aortic pathology, although the mode of death could
not be determined for most deaths (Table E6).Reoperation
There were 28 aortic valve reoperations. Overall unad-
justed freedom from reoperation was 99%, 97%, 92%,
and 89% at 30 days and 1, 5, and 10 years, respectively
(Figure E4). Risk was highest in the first 18 months, but
at 7 years, risk of reoperation for matched bioprostheses
crossed the repair hazard function curve (Figure E5). Free-
dom from reoperation at 10 years was 85% after remodel-
ing, 86% after reimplantation, and 91% after sinotubular
junction tailoring, with no statistically significant difference
among procedures (P>.4; Figure 3).
For reference, Figure 3 also shows age-matched reopera-
tion for structural valve deterioration for bovine pericardial
aortic valve bioprostheses. Procedures performed in pa-
tients with tricuspid aortic valves were associated with
lower risk of reoperation than for those with a bicuspid
valve (P ¼ .002; Table 2, Figure 4). Indeed, at 7 years,
when bioprostheses increasingly started to fail, the advan-
tage was approximately 2% over repairs, and at 11 yearsRemodeling
(total n ¼ 72)
Tailoring
(total n ¼ 222)
PNo. (%) n* No. (%)
0 (0) 199 9 (4.5) .07y
0 (0) 216 3 (1.4) .4y
19 (34) 199 103 (52) .002
13 (23) 199 71 (36) .006
6 (11) 199 54 (27) .001
2 (2.8) 222 16 (7.1) .02y
0 (0) 222 4 (1.8) .5y
6 (5–10)x 199 8 (5–21)x <.0001
ta available. yFisher’s exact test. zNo. refers to number of patients who received blood
. Thus, 30% of patients undergoing reimplantation and for whom data were available
diovascular Surgery c Volume 142, Number 6 1493
FIGURE 1. Unadjusted survival stratified by operative procedure. Each symbol represents a death, vertical bars represent asymmetric 68% confidence
limits (CL) equivalent to1 standard error, and numbers in parentheses represent patients remaining at risk. Solid lines are independently derived parametric
survival estimates enclosed within dashed 68% CLs. Patients remaining at risk appear at the bottom of the figure. For reference, the dot-dash-dot line is
survival for a matched US population, and dash-dot-dot-dot line matched survival after AVR for entire group. AVR, Aortic valve replacement.
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durability.
Other underlying pathologies were not associated with
difference in propensity-adjusted risk of reoperation (P>
.08; Table 2, Figure 5). It is interesting that among those
in whom tailoring was performed, the most common indica-
tion for reoperation was stenosis (Table 3). Clearly, overly
vigorous tailoring in an attempt to reduce regurgitation
can produce aortic valve stenosis.
DISCUSSION
Principal Findings
This study shows that excellent results, with few reoper-
ations and low mortality, can be achieved with aortic valveFIGURE 2. Survival according to underlying pathology. Format is as in Figure 1
an actuarial estimate at time of death (purple filled circle). AVR, Aortic valve r
1494 The Journal of Thoracic and Cardiovascular Surand root-preserving procedures for a diverse group of pa-
thologies. Indeed, the approximate 95% freedom from re-
operation at 12 years for tricuspid valves is encouraging
and better than for biologic valves. As expected, age, aortic
dissection, and degenerative aneurysms were strongly asso-
ciated with worse late survival; no other factor, including
type of root-preserving procedure and cause of root pathol-
ogy, was a risk factor for reduced late survival. Survival
after reimplantation and remodeling operations, and in pa-
tients with Marfan syndrome and bicuspid valves after op-
eration, despite severity of disease, was better than that of
their counterparts in the general population and consider-
ably better than that of patients with bioprostheses. More-
over, patients with bioprostheses were more likely to die. Single death among patients withMarfan syndrome is represented only by
eplacement.
gery c December 2011
FIGURE 3. Unadjusted freedom from reoperation according to procedure. Format is as in Figure 1. For reference, dot-dash-dot line represents age-
matched reoperation for structural valve deterioration of an aortic valve bioprosthesis.
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increasing valve failure, with further divergence from repair
and US population survival curves. This is gratifying. In-
deed, in patients with Marfan syndrome (one of the more
extensively studied subgroups), for whom the average age
of death used to be 32 years, 10-year survival was 100%,
and survival is now more than 70 years unless they have un-
dergone surgery for aortic dissection; then, 5-year survival
is only 50% to 70% after surgery.33,34
The finding that a longer aortic clamp time and an ele-
phant trunk procedure decreased early survival is not sur-
prising, because these variables are markers of more
extensive and complex operations. Nevertheless, we have
reported 98% 30-day survival for recently operated patients
undergoing an elephant trunk procedure.35 Late survivalwas
similar after reimplantation and remodeling root-preserving
procedures. Less invasive surgery was also associated with
higher early mortality in these complex operations. Thus,
more recently, a minimally invasive approach has been
used only for root remodeling or tailoring, but not for reim-
plantation of the aortic valve or arch procedures.TABLE 2. Incremental risk factors for reoperation
Variable Coefficient ± SE P
Reliability
(%)*
Type of procedure
Reimplantation vs tailoring 0.60  0.60 .3 28
Remodeling vs tailoring 0.41  0.50 .4 28
Propensity score for
reimplantation group
0.55  1.3 .7 —
Propensity score for
remodeling group
2.1  1.6 .2 —
Bicuspid aortic valve 1.4  0.50 .002 58
SE, Standard error. *Percent of time factor appeared in 1000 bootstrap analysis.
The Journal of Thoracic and CarNonadjusted risk of reoperation was influenced by the
presence of a bicuspid aortic valve; nevertheless, freedom
from reoperation was 77% at 10 years for such patients,
comparable to a previous report of 79% for isolated bicus-
pid aortic valve repairs without root or ascending aorta re-
pairs. Despite failures, reoperations were successful in
achieving 10-year survival of 93% and 15-year survival
of approximately 92% in these patients. Even so, we are ex-
ploring new options to achieve even better results, similar to
the 97% 9-year freedom from reoperation achieved in pa-
tients with tricuspid aortic valves.36-39 There have been
reports that remodeling may be associated with a greater
risk of reoperation, particularly in patients with Marfan
syndrome.3,13,17 Failures in the Marfan group were with
remodeling operations, not reimplantation, as we have
previously reported.34
In this study, operative procedure was selected according
to underlying pathology as described in the ‘‘Patients and
Methods’’ section, and the results are nearly superimpos-
able for freedom from reoperation for the modified David
reimplantation, remodeling, or sinotubular junction tailor-
ing. David and colleagues,8,10,17 Sarsam and Yacoub,9 and
others3,5,12,14,15,19,23,40 have also reported excellent late
results with both reimplantation and remodeling. Of
interest, we referenced survival to the general population
and found that, following the initial early hazard phase
after operation, the hazard function of our patients for
mortality closely tracked that of the population. We also
referenced aortic valve reoperation to expected
reoperation based on structural valve deterioration of
bioprostheses, which is known to be age related. We
found that few (n ¼ 1) of the reoperations for our patients
were for structural valve deterioration, but for other
earlier indications. Moreover, it should be noted thatdiovascular Surgery c Volume 142, Number 6 1495
FIGURE 4. Unadjusted freedom from reoperation after bicuspid or tricuspid valve procedure (P ¼ .002). Format is as in Figure 1. Dash-dot-dash line
represents age-matched reoperation for structural valve deterioration of an aortic valve bioprosthesis.
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10 years, except bicuspid valves (the latter 14 years by
extrapolation), the additional benefits of repair are better
survival, better hemodynamics, and less risk of stroke and
endocarditis.1 Of note, we have previously reported the he-
modynamic benefits with our modification of the David re-
implantation, which provides both excellent effective
orifice areas and low transvalvular pressure gradients with
valve reimplantation.37
Limitations
This was not a randomized study designed to compare
root-sparing procedures, although we have used propensity
scores to balance variables to reduce selection bias. A ran-FIGURE 5. Unadjusted freedom from reoperation according to underlying pa
patients are depicted by actuarial estimates only (purple filled circles). Note tha
going remodeling, not reimplantation.
1496 The Journal of Thoracic and Cardiovascular Surdomized study would be difficult to perform, because pro-
cedure selection is influenced by the underlying
pathologies and operative findings based on the Commis-
sures, Leaflets, Anulus, Sinotubular junction, and Sinuses
(CLASS) schema.1,38 Furthermore, randomizing patients
with repairable valves to repair or replacement on the
basis of this study and others does not seem to be justified.
Although this is a 2-institution study, it traces sequential
results of mainly one of the surgeons (LGS) at both venues.
Thus, this should be considered a single experience. Be-
cause volume of these procedures has increased in recent
years, average follow-up is short. However, time-related
methods permit analysis of patients who underwent opera-
tion early in the series, for whom follow-up is long.thology. Format is as in Figure 1. Two events among the Marfan syndrome
t in patients with Marfan syndrome, the 2 failures occurred in those under-
gery c December 2011
TABLE 3. Indications for reoperation by procedure
Factor
Procedure
Reimplantation
(n ¼ 7)
No. (%)
Remodeling
(n ¼ 8)
No. (%)
Tailoring
(n ¼ 14)
No. (%)
Regurgitation 0 (0) 2 (25) 3 (21)
Stenosis 0 (0) 1 (13) 4 (29)
Endocarditis 3 (43) 0 (0) 2 (14)
New aneurysm or aortic
dilatation
0 (0) 0 (0) 3 (21)
Aortic dissection 0 (0) 0 (0) 1 (7.1)
Failed repair 0 (0) 4 (50) 0 (0)
SVD 1 (14) 0 (0) 0 (0)
Uncertain 3 (29) 1 (13) 1 (7.1)
SVD, Structural valve deterioration.
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DCONCLUSIONS
On the basis of the excellent results of this study and
other reports, we recommend that young patients with aortic
valve regurgitation accompanying aortic root pathology be
managed by teams experienced in aortic valve-preserving
procedures. This is because management of the root re-
quires matching the appropriate operative procedure to
the underlying pathology. Long-term benefits include ex-
cellent survival, freedom from prosthesis-related complica-
tions, and low risk of reoperation.
For patients with a tricuspid valve, even if associated with
severe regurgitation, and no large cusp perforations, we rec-
ommend a reimplantation type of operation. For patients
with bicuspid valves having little calcium and no stenosis,
we recommend a tailoring procedure with leaflet repair or
a root remodeling procedure. If patients have splaying of
the sinotubular junction and less than severe regurgitation
or leaflet pathology, a tailoring procedure is associated
with good results.References
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FIGUREE1. Unadjusted overall survival after operation. Note decline in survival after 7.5 years in biologic AVR patients. Each symbol represents a death,
vertical bars represent asymmetric 68% confidence limits (CLs) equivalent to1 standard error, and numbers in parentheses represent patients remaining at
risk. Solid line is an independently derived parametric survival estimate enclosed within dashed 68% CLs. For reference, dash-dot-dash line is survival for
a matched US population, and dash-dot-dot-dot line matched survival after AVR for entire group. AVR, Aortic valve replacement.
FIGURE E2. Unadjusted overall hazard function (instantaneous risk) for death. Note increase in deaths after 7.5 years in biologic AVR patients. Solid line
is hazard estimate enclosed within 68% CLs. For reference, dot-dash-dot line is hazard function for matched US population, and dash-dot-dot-dot line is
hazard function for matched population after AVR for entire group. AVR, Aortic valve replacement.
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FIGURE E3. Unadjusted 2-year survival according to aortic clamp time.
FIGURE E4. Unadjusted freedom from aortic valve reoperation. Format is as in Figure E1. Dash-dot-dash line represents age-matched reoperation for
structural valve deterioration of an aortic valve bioprosthesis.
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FIGURE E5. Unadjusted hazard function for reoperation. Note increasing rate of reoperation after 7 years in patients with aortic valve bioprostheses.
Format is as in Figure E2, except that dash-dot-dash line is for age-matched rate of structural valve deterioration of aortic valve bioprostheses.
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TABLE E1. Patient characteristics and operative details according to aortic valve-preserving technique
Variable
Reimplantation
(total n ¼ 72)
Remodeling
(total n ¼ 72)
Tailoring
(total n ¼ 222)
Pn* No. (%) or mean ± SD n* No. (%) or mean ± SD n* No. (%) or mean ± SD
Demography
Male 72 55 (76) 72 55 (76) 222 146 (66) .09
Age (y) 72 50  15 72 51  16 222 60  15 <.0001
Height (cm) 63 179  9.5 56 180  11 199 172  11 <.0001
Weight (kg) 63 89  20 56 89  16 199 83  20 .003
Body surface area (m2) 63 2.1  0.27 56 2.1  0.23 199 2.0  0.28 .0004
Clinical status
NYHA class 63 56 199 .09y
I 32 (51) 20 (36) 81 (41)
II 27 (43) 26 (46) 81 (41)
III 4 (6.4) 8 (14) 23 (12)
IV 0 (0) 2 (3.6) 14 (7)
Emergency operation 71 2 (2.8) 71 14 (21) 218 73 (33) <.0001
Aortic pathophysiology
Aortic dissection 72 11 (15) 72 19 (26) 222 102 (46) <.0001
Marfan syndrome 72 23 (32) 72 12 (17) 222 3 (1.3) <.0001
Annuloaortic ectasia 72 9 (13) 72 10 (14) 222 0 (0) <.0001z
Bicuspid aortic valve 72 5 (6.9) 72 17 (24) 222 52 (23) .008
Cardiac comorbidity
Coronary artery diseasex 71 9 (13) 72 16 (22) 219 69 (32) .005
Preoperative AV regurgitation grade 72 71 222 .3y
0 9 (13) 16 (23) 23 (10)
1þ 8 (11) 12 (17) 37 (17)
2þ 16 (22) 22 (31) 63 (28)
3þ 26 (36) 14 (20) 54 (24)
4þ 13 (18) 7 (9.9) 45 (20)
Ejection fraction (%), echo 68 57  7.7 67 56  9.5 185 57  10 .9
Noncardiac comorbidity
Previous stroke 72 4 (5.6) 72 4 (5.6) 222 23 (10) .3
Peripheral arterial disease 72 8 (11) 72 10 (14) 222 46 (21) .12
Cholesterol (mg $ dL1) 51 194  30 37 193  36 135 188  41 .6
Triglycerides (mg $ dL1) 51 166  100 34 147  76 134 138  99 .05
Creatinine (mg $ dL1) 71 0.95  0.25 71 1.0  0.30 215 1.3  1.4 .05
Procedural
Less invasive approach 72 5 (6.9) 72 9 (13) 221 15 (6.8) .3
Operative extent 72 72 222
Ascending aorta 36 (50) 30 (42) 59 (27) .0004
Ascending and archk 27 (38) 31 (43) 163 (73) <.0001
Distal arch 0 (0) 1 (1.4) 0 (0) .4z
Concomitant aortic procedure
Descending aorta 55 1 (1.8) 66 7 (11) 186 16 (8.6) .1z
Descending aorta elephant trunk graft 72 4 (5.6) 72 3 (4.1) 221 23 (10) .16
Thoracoabdominal 55 2 (3.6) 66 1 (1.5) 186 16 (8.6) .16
Concomitant CABG 72 7 (9.7) 72 16 (22) 221 58 (26) .02
CPB time (min) 70 140  25 72 137  41 214 116  50 <.0001
Aortic clamp time (min) 71 114  21 72 100  35 213 73  36 <.0001
AV, Aortic valve; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; NYHA, New York Heart Association; SD, standard deviation. *Data available.
yCochran–Mantel–Haenszel statistic. zFisher’s exact test. xNumber of systems with 50% stenosis. kArch refers to total arch or hemiarch replacement. Note that more patients
undergoing tailoring had arch repairs, likely reflecting older age, more extensive disease, emergency operation, and aortic dissection. When the arch is not dilated, arch replace-
ment is avoided except in cases of aortic dissection.
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TABLE E2. Factors considered in multivariable models
Preoperative
Demography: Gender, age at operation (y), height (cm), weight (kg), body surface area (m2), body mass index (kg $ m2)
Symptoms: New York Heart Association functional class (I–IV), Canadian Angina class (0–4), emergency operation
Ventricular function: Infarction on echocardiogram, myocardial infarction, left ventricular ejection fraction
Pathology: Aortic dissection, Marfan syndrome, bicuspid aortic valve, aortic valve regurgitation, aortic valve regurgitation grade
Cardiac comorbidity: Atrial fibrillation, ventricular arrhythmia, stroke
Noncardiac comorbidity: History of smoking, history of peripheral arterial disease, previous stroke, creatinine, coronary artery disease
Operative
Support: Cardiopulmonary bypass time (min), aortic clamp time (min)
Surgery type: Ascending aorta, ascending aortaþarch, reimplantation, remodeling, number of sinuses remodeled in patients undergoing
remodeling, resuspension, descending elephant trunk graft, coronary artery bypass grafting, number of coronary
arteries bypassed, minimally invasive procedure, coronary arteries implanted into graft
Experience: Date of operation
TABLE E3. Factors associated with type of procedure performed*
Variable
Reimplantation vs tailoring
(coefficient ± SE) P
Remodeling vs tailoring
(coefficient ± SE) P
Agey 1.3  0.21 <.0001 0.92  0.19 <.0001
Emergency operation 3.3  0.75 <.0001 0.85  0.37 .02
Bicuspid aortic valve 3.2  0.58 <.0001 1.0  0.39 .008
Aortic regurgitation 0.31  0.14 .03 0.21  0.12 .07
Date of operationz 1.9  0.45 <.0001 0.78  0.33 .02
SE, Standard error. *Parsimonious polytomous model. y(Age/50), exponential transformation. zLn(date), natural logarithmic transformation.
Svensson et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 142, Number 6 1498.e5
A
C
D
TABLE E4. Propensity model for type of procedure performed*
Variable
Reimplantation vs tailoring
(coefficient ± SE) P
Remodeling vs tailoring
(coefficient ± SE) P
Male 1.0  0.42 .02 0.38  0.36 .3
Agey 1.2  0.25 <.0001 0.90  0.22 <.0001
Emergency operation 3.4  0.78 <.0001 0.78  0.39 .04
Ejection fractionz 0.74  0.98 .5 0.36  0.72 .6
CAD 0.83  0.48 .08 0.11  0.38 .8
PAD 0.42  0.52 .9 0.07  0.44 .9
Stroke 0.04  0.65 >.9 0.49  0.60 .4
History of smoking 0.20  0.36 .6 0.015  0.32 >.9
Creatinine 0.66  0.55 .2 0.34  0.26 .2
Bicuspid aortic valve 3.5  0.60 <.0001 1.2  0.40 .004
Aortic regurgitation 0.40  0.16 .01 0.21  0.12 .08
Date of operationx 2.0  0.48 <.0001 0.79  0.34 .02
CAD, Coronary artery disease; PAD, peripheral arterial disease; SE, standard error. *Polytomous model. y(Age/50), exponential transformation. zLn(ejection fraction), logarith-
mic transformation. xLn(date), natural logarithmic transformation.
TABLE E5. Incremental risk factors for death
Variable Coefficient ± SE P
Reliability
(%)*
Early hazard phase
Type of procedure 14
Reimplantation vs
tailoring
0.32  0.93 .7
Remodeling vs tailoring 1.2  1.1 .3
Propensity score for
reimplantation group
3.6  2.4 .1 —
Propensity score for
remodeling group
3.6  3.3 .3 —
Older agey 0.88  0.38 .02 53
Less invasive procedure 2.0  0.70 .004 52
Longer aortic clamp timez 0.32  0.089 .0004 54
Elephant trunk graft 1.2  0.58 .04 57
Cleveland Clinic vs Lahey 1.9  1.3 .1 —
Late hazard phase
Type of procedure 12
Reimplantation vs
tailoring
0.31  0.56 .6
Remodeling vs tailoring 0.094  0.45 .8
Propensity score for
reimplantation group
2.1  1.4 .1 —
Propensity score for
remodeling group
3.1  2.1 .1 —
Older agey 0.62  0.2 .002 99
Cleveland Clinic vs Lahey 0.83  0.58 .2 —
Pathology 56
Dissection 1.8  0.63 .005
Degeneration 1.6  0.69 .02
SE, Standard error. *Percent of time factor appeared in 1000 bootstrap analyses. Fac-
tors represented in 50% or more of models are considered reliable (50% probability
that P .05). y(Age/50), exponential transformation. z(Aortic clamp time/80), expo-
nential transformation.
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TABLE E6. Mode of late death by pathology
Factor
Pathology
Aortic dissection
(n ¼ 48) No. (%)
Marfan syndrome
(n ¼ 1) No. (%)
Bicuspid aortic valve
(n ¼ 4) No. (%)
Degeneration
(n ¼ 36) No. (%)
Cardiac 1 (25)
Heart failure 3 (6.3) 1 (2.8)
Endocarditis 1 (25)*
Arrhythmia 1 (2.8)
Ischemia 2 (5.6)
NOS 1 (2.1) 1 (2.8)
Aneurysm rupture or
dissection
3 (6.3) 1 (2.8)
Sudden 3 (6.3) 1 (2.8)
Stroke 4 (8.3) 2 (5.6)
Respiratory failure 3 (6.3) 2 (5.6)
Pulmonary embolism 1 (25)
Renal failure 2 (4.2)
Gastrointestinal 1 (2.1)
Cancer 2 (4.2) 4 (11)
Sepsis 1 (2.1)
Trauma 2 (4.2)
Noncardiac (NOS) 1 (2.8)
Systemic inflammatory
response syndrome
1 (2.1) 1 (2.8)
MSOF 2 (4.2) 1 (2.8)
Uncertain 20 (42) 1 (100) 1 (25) 18 (50)
MSOF, Multiple system organ failure; NOS, not otherwise specified. *Died at reoperation.
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